Merck & Co diversifies its oncology portfolio further by acquiring VelosBio for $2.75bn

Merck & Co diversifies its oncology portfolio further by acquiring VelosBio for $2.75bn

$56.88

Available Options

merck horizon blue cross blue shield
Merck & Co diversifies its oncology portfolio further by acquiring VelosBio for $2.75bn

A total of 3 guests made comments

2026-04-12

The product is practical, solid, and of reliable quality.

2026-04-08

I’m happy with how reliable and easy to use it is.

2026-04-07

The packaging was secure, and the delivery was on time.

Add a review

Your email address will not be published. Required fields are marked

Your rating

Related Products